Abstract: There is disclosed a method of reducing the level of saturated fatty acids relative to the level of unsaturated fatty acids in bovine milk by determining which cows of a herd produce milk containing β-casein having a proline at position 67, by testing genetic material of individual cows of the herd for the presence of DNA encoding β-casein having a proline residue at position 67 or by testing milk produced by individual cows of the herd for the presence of β-casein having a proline at position 67; selecting cows having DNA encoding β-casein with a proline residue at position 67 or that produce milk containing β-casein having a proline at position 67; and milking the selected cows to give milk having a reduced level of saturated fatty acids relative to the level of unsaturated fatty acids compared with milk obtained from the herd.
This application has been divided out of the Indian Patent Application Number
123/KOLNP/2005
TECHNICAL FIELD
This invention relates to a method for reducing the level of saturated fatty acids relative
to the level of unsaturated fatty acids in milk. In particular, the invention relates to the
genotyping and/or phenotyping of bovine cows on the basis of the amino acid residue
located at position 67 of (3-casein produced in their milk.
BACKGROUND
Dietary saturated fatty acids intake is known to be a major risk factor in heart disease in
humans, particularly in countries where the population is well-nourished. Animal
products, such as dairy products (especially milk), are major contributors to the dietary
intake of humans. It is generally accepted that the level of saturated fatty acids found in
milk, particularly those with a chain length of less that 18 carbon atoms, is a risk factor
in coronary heart disease. In contrast, unsaturated fatty acids are considered to be
beneficial. Because of this, there has been a preference for the consumption of plant
derived oils as opposed to animal based products.
The medical community is also concerned about the consumption of fat found in milk
because of the abundance of the saturated fatty acid C:14:0, which is thought to be
atherogenic. The dairy industry has in part responded with the production of "low fat"
milk alternatives using chemical separation and extraction techniques.
In addition to fats, specific protein components of milk, including the A1 variant of the (3-
casein protein, are health risk factors. There are a number of reports that the
consumption of [3-casein A1 by humans is linked with a higher incidence of certain
diseases, specifically diabetes (Elliott et al. 1999 Diabetologia 42:292-6;
-1a-
Wasmuth et al. 1999 Diabetologia 42 (Suppl.1):A88 Proceedings of the Kongress der
Europaischen Diabetesgesellschaft vom 28.-30.09.1999 in Brussels/Belgium) and
coronary heart disease (McLachlan, C.N., Med. Hypotheses 56(2):262-72, 2001).
In addition to phenotyping a cow by identifying the particular (3-casein variant or variants
produced in the cow's milk, it is well known that a cow can be genotyped for a specific
single nucleotide polymorphism (SNP) to determine which (3-casein variant or variants
she will produce in her milk. A method of selecting bovine cows on the basis of this
genotyping methodology to give milking herds which will produce milk free of the 3-
casein A1 variant, and preferably solely the (3-casein A2 variant, is the subject of
PCT/NZ96/00039 (published as WO 96/36239).
The applicant has now found that there is a correlation between the ratio of saturated to
unsaturated fatty acids in milk and the p-casein variants in milk. While there are known
methods of altering the fatty acid composition of animal products, these typically include
chemical extraction, specific feeding and management systems, and quantitative
genetic selection for levels of specific fatty acids in milk. Each method is costly and
usually inefficient.
It is therefore an object of the invention to provide milk, or a product obtained from that
milk, which has a reduced level of saturated fatty acids relative to unsaturated fatty
acids, or to at least provide the public with a useful alternative.
STATEMENTS OF INVENTION
In a first aspect of the invention there is provided a method of reducing the level of
saturated fatty acids relative to the level of unsaturated fatty acids in bovine milk by:
(a) determining which cows of a herd produce milk containing 3-casein having a
proline at position 67, where the herd comprises cows that produce milk
containing p-casein having a proline at position 67 and cows that produce milk
3-casein having a histidine at position 67, by testing genetic material of
2
individual cows of the herd for the presence of DNA encoding (3-casein having
a proline residue at position 67 or by testing milk produced by individual cows
of the herd (or a product produced from that milk) for the presence of (3-casein
having a proline at position 67;
(b) selecting cows that have DNA encoding P-casein having a proline residue at
position 67 or cows that produce milk containing P-casein having a proline at
position 67; and
(c) milking the selected cows to give milk having a reduced level of saturated fatty
acids relative to the level of unsaturated fatty acids compared with milk
obtained from the herd.
It is preferred that the p-casein having a proline at position 67 includes one or more of
P-caseins A2, A3, D, E and F. It is also preferred that the P-casein having a histidine at
position 67 includes one or more of p-caseins A1, B, and C.
In a preferred embodiment of the invention the p-casein having a proline at position 67
is p-casein A2 and the p-casein having a histidine at position 67 is p-casein A1.
It is further preferred that, in addition to reducing the level of saturated fatty acids
relative to the level of unsaturated fatty acids in the milk produced by the herd of cows,
the level of short and medium chain saturated fatty acids having 6 to 14 carbon atoms in
each chain (C6:0-C14:0) is also reduced.
In a further preferred embodiment of the invention, determining which cows of the herd
produce milk containing p-casein having a proline at position 67 is by testing the genetic
material of cows for the presence of DNA encoding p-casein having a proline residue at
position 67. In an alternative embodiment, determining which cows of the herd produce
milk containing p-casein having a proline at position 67 is by testing the milk produced
by cows (or a product produced from that milk) for the presence of p-casein having a
proline at position 67.
3
While the genetic material of the cow may be any tissue containing, or which contained,
nucleated cells, the genetic material is preferably obtained from blood, hair, or milk.
In a second aspect of the invention there is provided milk obtained by the method of the
first aspect of the invention.
In a third aspect of the invention there is provided a milk product prepared from milk
obtained by the method of the first aspect of the invention.
In a fourth aspect of the invention there is provided a method of altering the proportions
of saturated fatty acids and unsaturated fatty acids in a food by adding to the food an
amount of p-casein having a proline at position 67.
Preferably the proportions of saturated fatty acids and unsaturated fatty acids are
altered by reducing the level of saturated fatty acids in the food.
Preferably the food is milk or a milk product prepared from milk. It is also preferred that
the p-casein having a proline at position 67 is added to the food by adding milk (or an
extract from milk) obtained by the method of the first aspect of the invention.
DETAILED DESCRIPTION OF THE INVENTION
It is well known that the genetics of an animal has a substantial impact on production
levels and product quality, and on health, environmental, and animal welfare issues.
The ability to determine a phenotype of an animal by using a genetic test is a valuable
tool for achieving rapid identification of animals and animal products with beneficial
characteristics and for forming a group of animals having enhanced production and/or
product quality. Animals can be grouped based on genetic differences that relate to
animal or animal product traits that are of economic interest.
The gene (or variant of that gene) that is responsible for a particular physical trait of an
animal may, in some instances, be identifiable by a single nucleotide polymorphism
4
(SNP). An SNP is a DNA sequence at a location in an animal's genome which is
different to the DNA sequence at the same location in the genome of another animal by
virtue of only one nucleotide. Even a difference as small as this can mean one animal
exhibits a particular physical trait whereas another animal does not.
Associations between the casein content and the fat content of milk have been
identified, but these have been variable in the size and direction of the correlation. The
results are therefore inconclusive. Bovenhius and Weller (Genetics;137(10):267-80,
1994) concluded that the associations, where they exist, are due to linkage (in a sire
pedigree) or linkage disequilibrium (in a population) with a fat QTL on the same cattle
chromosome ( chromosome 6). The overall conclusion from published data is that the
total amount of fat in milk is not related to p-casein genotype and that the effect or
effects that p-casein may have on human health are not related to the volume of fat
intake. However, the applicant has now identified an unexpected relationship between
the genotype of the p-casein gene on cattle chromosome 6 and the fatty acid
composition of cow milk.
The applicant has confirmed prior findings that milk which contains p-casein A1 (A1 milk)
has a similar overall percentage of fat compared with milk which is free of p-casein A1
(A2 milk). Surprisingly, and contradictory to previous findings, the applicant has
discovered that A1 milk has a higher percentage of saturated fatty acids and a lower
percentage of unsaturated fatty acids compared to A2 milk. Also surprising was the
finding that the levels of C6, C8, C10, C12 and C14 fatty acids were reduced in milk
from those cows homozygous for p-casein A2. This significant finding shows that milk
which is substantially free of p-casein A1 will also produce milk fat that has lower levels
of saturated fatty acids and medium chain fatty acids (C6 to C14) and higher levels of
unsaturated fatty acids. Therefore, this milk has the health benefit of the reduced risk of
diseases associated with a high intake of saturated fatty acids, such as atherosclerosis,
obesity, coronary heart disease, and diabetes.
Typically, a cow will produce p-caseins in its milk. However, different P-casein variants
exist including A1, A2, A3, B, C, D, E, and F. The differences between these proteins are
determined by sequence variations in the p-casein gene. For example, one difference
5
is that the A2, A3, D, E, and F variants have a proline residue at position 67 whereas the
A1, B, and C variants have a histidine residue at position 67. This difference is
determined by substitution of the nucleotide adenine with the nucleotide cytosine at
position 200 of the coding region of the p-casein gene. The p-casein variant phenotype
of a cow can be determined indirectly by genotyping the SNPs that are responsible for
distinguishing these variant types.
The applicant has discovered that the selection of animals on the basis of p-casein
variant type or the genetic variation in the (B-casein gene can identify groups of animals
with significant differences in their milk fatty acid compositions. For example, milk from
animals which are homozygous for the adenine nucleotide at position 200 of the coding
region of the p-casein gene (A1) differs in fatty acid composition from milk from animals
which are heterozygous for an adenine and cytosine nucleotide (A1/A2) at this position,
which differs again from milk from animals which are homozygous for a cytosine at this
position (A2).
More specifically, an adenine at position 200 of the p-casein gene increases levels of
the saturated fatty acids C6:0, C8:0, C10:0, C12:0 and C14:0 and decreases
unsaturated fat C18:1 by a comparable amount. On removal from consideration of the
effects of herd, mob within herd, breed, age 2-8+, days in milk, methylation group, and
sire, the p-casein genotype accounts for 15-20% of the variation in these specific fatty
acid profiles between animals.
The presence of a histidine at position 67 of p-casein enables the enzymatic formation
of p-casomorphin-7. p-Casomorphin-7 is a seven amino acid peptide that is formed only
from p-caseins A1, B and C. Casomorphin peptides are known to act as opioids. Data
from Lin et al. (1998, Peptides 19(2):325-31) suggest that P-casomorphin-7 may
modulate the intake of dietary fat. p-Casomorphins stimulate the intake of dietary fat in
rats whereas enterostatin inhibits the intake. In addition, it has been found that peptides
from casein hydrolysates with tyrosyl end residues (such as p-casomorphin-7) promote
peroxidase-dependent oxidation of human LDLs (low density lipoproteins). Thus, the
current understanding of p-casein A1, in terms of its relationship to factors that are
detrimental to human health, is related to the action of casein, and peptides derived
6
from it, on the fat metabolism of the consumer and not related to differences in the fat
composition of milk from animals of different p-casein genotype.
It is unlikely that the mechanism whereby |3-casein affects the fatty acid composition of
milk is due to a linked gene. This is because of the size and consistency of the effect
observed across sires. Without placing any limitation on the invention, it is speculated
that the discovery is related to a direct effect of (3-casein on the biosynthesis of lipids in
mammary tissue. Alternatively, the discovery may be a direct result of the interactions
of caseins with lipids in milk. If the latter is correct, it may be possible to alter the fatty
acid profile of a product. Thus, the addition of (3-casein obtained from animals of
selected casein variant type (for example, free of P-casein A1) to a product under
defined processing conditions may beneficially alter the fatty acid profile of the product.
The test for P-casein can be used to select animals to include in a herd for milking or
can be used to select animals to be used as sires, dams, or tissue donors for artificial
breeding or cloning to breed subsequent generations of animals to be included in a herd
for milking. In this way, herds of milking cows can be formed which produce milk where
the (J-casein A1 protein is absent (or where the only p-casein present is p-casein A2) in
the protein fraction of the milk, and having reduced levels of specific saturated fatty
acids and increased levels of a specific unsaturated fatty acids in the fat fraction of the
milk. A method of selecting bovine cows on the basis of such genotyping to form
milking herds which will produce milk free of the p-casein A1 variant, and preferably
solely the p-casein A2 variant, is the subject of PCT/NZ96/00039 (published as WO
96/36239).
An additional feature of the invention is that once animals with a particular genotype
have been selected and milk is produced from them, the origin of the milk, or other
products, such as milk powder and processed milk products, can be verified as being
produced from the selected animals. This is achieved by determining the fatty acid
composition of such a milk product. Consumers can therefore be confident that the milk
is indeed from animals of the desired genotype.
The benefits of the milk of this invention are considerable:
7
(1) the absence of (i-casein A1 protein and the presence of only (3-casein A2
produces a lower risk of coronary heart disease and Typei diabetes
(2) replacing saturated fat with unsaturated fat produces a lower risk of coronary
heart disease, obesity and other diseases
(3) the consumption of C14:0, which is thought to be atherogenic, is reduced.
The mechanism by which casein effects the fatty acid composition of milk is unclear but
it is possible that it is mediated though the formation of casomorphin peptides from
casein. There may be a mechanistic relationship between this and the effect of the
consumption of p-casein A1 by humans. However, the direct effect of casein genotype
on the fatty acid profile of milk has quite separate utility from the direct effects of casein
and casein metabolites on the metabolism of the consumer. There may also be a direct
effect, whereby (i-caseins (or particular variants) can directly modify the fatty acid
composition of milk.
EXAMPLES
DNA was extracted and the fatty acid compositions determined from milk from 1114
progeny derived from six sires which were heterozygous A/C at nucleotide 200 of the 3-
casein gene.
DNA was extracted from the milk in the following way. Milk was mixed thoroughly by
inversion and 1.0 ml was pipetted into a 1.5 ml microcentrifuge tube. The tubes were
centrifuged at 8,000 rpm for 10 minutes and a 100 pi aliquot of supernatant (containing
crude DNA) pipetted from each sample into a new 1.5ml tube. The crude DNA extract was
stored frozen at -20°C and 1-5 ul was used, without further purification, for genotyping.
Genotyping methods used were have been described previously in detail in
PCT/NZ96/00039 (published as WO 96/36239).
8
The samples for fatty acid analysis were centrifuged at 15,000 rpm for 15 minutes. An
aliquot of the upper layer of lipid was removed from each sample. This lipid sample was
heated to 60.0°C and the melted lipid removed, and stored frozen. The samples were
subsequently methylated and analysed by gas chromatography. The peak areas on
chromatographs were integrated to quantify the levels each fatty acid. The identity of
each fatty acid was determined by comparing the retention time of each peak with a
known standard.
Of the samples analysed, animals either tested CC (A2), AC (A1/A2) or AA (A1) at
position 200. The differences between genotypes were compared using generalised
linear model analysis where the raw data was adjusted for other factors which might
affect fatty acid composition. Pre-adjustments were made for: Herd, Mob within Herd,
Breed, Age 2-8+, Days in Milk, and Methylation Group within Herd. Finally, Sire,
Genotype, and Sire by Genotype interaction were fitted.
The results from this study are given in Table 1 and show that the A2 genotype had a
significant effect on fatty acid composition. The levels of statistical significance varied
between individual fatty acids (* =p<0.05, **=p<0.1 ***=p<0.001). Compared to A1, milk
from animals with the A2 genotype had a significantly higher percentage of long chain
unsaturated fatty acids (C18:1) and a lower percentage of saturated medium chain fatty
acids in the range (C6:0-C14:0); whereas A1/A2 individuals were intermediate for these
values.
As a percentage of the total C18:1, A2-derived milk had about 3% more C18:1 than A1-
derived milk. C18:1 makes up about 15% of milk fat so the overall effect as a proportion
of total milk fat was about half a percent more C18:1. The reduction in the percentage
of saturated fatty acids was similar to the increase in unsaturated fatty acid. With the
effects of herd, mob within herd, breed, age 2-8+, days in milk, methylation group and
sire removed by the model, the (3-casein genotype accounted for 15-20% of the
variation in these specific fatty acid compositions between the animals.
9
Although the invention has been described by way of example, it should be appreciated
that variations and modifications may be made without departing from the scope of the
invention. Furthermore, where known equivalents exist to specific features, such
equivalents are incorporated as if specifically referred in this specification.
INDUSTRIAL APPLICABILITY
Milk having a low level of saturated fatty acids compared to unsaturated fatty acids is
useful for the avoidance of certain diseases and disorders. Dietary fatty acid intake is a
major risk factor in heart disease and much of that dietary fatty acid intake is from the
consumption of milk and milk products. The ability to obtain milk low in saturated fatty
acids relative to unsaturated fatty acids by milking only those cows that have been
genotyped or phenotyped on the basis of their ability to produce (3-casein variants
having proline, rather tnan nistidine, at position 67 represents a useful method oT
producing milk beneficial to human health.
11
We Claim
1. A method of reducing the level of saturated fatty acids relative to the level of
unsaturated fatty acids in bovine milk by:
(a) determining which cows of a herd produce milk containing p-casein having a
proline at position 67, where the herd comprises cows that produce milk
containing P-casein having a proline at position 67 and cows that produce milk
p-casein having a histidine at position 67, by testing genetic material of
individual cows of the herd for the presence of DNA encoding p-casein having
a proline residue at position 67 or by testing milk produced by individual cows
of the herd (or a product produced from that milk) for the presence of p-casein
having a proline at position 67;
(b) selecting cows that have DNA encoding p-casein having a proline residue at
position 67 or that produce milk containing p-casein having a proline at
position 67; and
(c) milking the selected cows to give milk having a reduced level of saturated fatty
acids relative to the level of unsaturated fatty acids compared with milk
obtained from the herd.
2. A method as claimed in claim 1 where the p-casein having a proline at position 67
includes one or more of p-caseins A2, A3, D, E and F.
3. A method as claimed in claim 2 where the p-casein having a proline at position 67
is P-casein A2.
4. A method as claimed in claim 1 where the p-casein having a histidine at position
67 includes one or more of p-caseins A1, B, and C.
12
6. A method as claimed in any one of claims 1 to 5 where the level of short and
medium chain saturated fatty acids having 6 to 14 carbon atoms in each chain
(C6:0-C14:0) is reduced compared with milk obtained from the herd.
7. A method as claimed in any one of claims 1 to 6 where determining which cows
of the herd produce milk containing (3-casein having a proline at position 67 is by
testing genetic material of cows for the presence of DNA encoding (3-casein
having a proline at position 67.
8. A method as claimed in any one of claims 1 to 7 where determining which cows
of a herd produce milk containing (3-casein having a proline at position 67 is by
testing the milk produced by cows (or a product produced from that milk) for the
presence of (3-casein having a proline at position 67.
9. A method as claimed in any one of claims 1 to 8 where the genetic material of
the cows may be any tissue containing, or which contained, nucleated cells.
10. A method as claimed in claim 9 where the genetic material is obtained from
blood, hair, or milk.
11. Milk obtained by the method as claimed in any one of claims 1 to 10.
12. A milk product prepared from milk obtained by the method as claimed in any one of
claims 1 to 10.
There is disclosed a method of reducing the level of saturated fatty acids relative to
the level of unsaturated fatty acids in bovine milk by determining which cows of a
herd produce milk containing β-casein having a proline at position 67, by testing
genetic material of individual cows of the herd for the presence of DNA encoding
β-casein having a proline residue at position 67 or by testing milk produced by
individual cows of the herd for the presence of β-casein having a proline at
position 67; selecting cows having DNA encoding β-casein with a proline residue
at position 67 or that produce milk containing β-casein having a proline at position
67; and milking the selected cows to give milk having a reduced level of saturated
fatty acids relative to the level of unsaturated fatty acids compared with milk
obtained from the herd.
| # | Name | Date |
|---|---|---|
| 1 | 1988-KOLNP-2007-FORM 3 1.1.pdf | 2011-10-07 |
| 2 | 1988-KOLNP-2007-CORRESPONDENCE 1.2.pdf | 2011-10-07 |
| 3 | 01988-kolnp-2007-form 5.pdf | 2011-10-07 |
| 4 | 01988-kolnp-2007-form 3.pdf | 2011-10-07 |
| 5 | 01988-kolnp-2007-form 2.pdf | 2011-10-07 |
| 6 | 01988-kolnp-2007-form 18.pdf | 2011-10-07 |
| 7 | 01988-kolnp-2007-form 1.pdf | 2011-10-07 |
| 8 | 01988-kolnp-2007-description complete.pdf | 2011-10-07 |
| 9 | 01988-kolnp-2007-correspondence others.pdf | 2011-10-07 |
| 10 | 01988-kolnp-2007-correspondence 1.1.pdf | 2011-10-07 |
| 11 | 01988-kolnp-2007-claims.pdf | 2011-10-07 |
| 12 | 01988-kolnp-2007-abstract.pdf | 2011-10-07 |
| 13 | 1988-KOLNP-2007-(11-06-2013)-PETITION UNDER RULE 137.pdf | 2013-06-11 |
| 14 | 1988-KOLNP-2007-(11-06-2013)-PETITION UNDER RULE 137-1.3.pdf | 2013-06-11 |
| 15 | 1988-KOLNP-2007-(11-06-2013)-PETITION UNDER RULE 137-1.2.pdf | 2013-06-11 |
| 16 | 1988-KOLNP-2007-(11-06-2013)-PETITION UNDER RULE 137-1.1.pdf | 2013-06-11 |
| 17 | 1988-KOLNP-2007-(11-06-2013)-PA.pdf | 2013-06-11 |
| 18 | 1988-KOLNP-2007-(11-06-2013)-OTHERS.pdf | 2013-06-11 |
| 19 | 1988-KOLNP-2007-(11-06-2013)-FORM-3.pdf | 2013-06-11 |
| 20 | 1988-KOLNP-2007-(11-06-2013)-FORM-2.pdf | 2013-06-11 |
| 21 | 1988-KOLNP-2007-(11-06-2013)-FORM-13.pdf | 2013-06-11 |
| 22 | 1988-KOLNP-2007-(11-06-2013)-FORM-1.pdf | 2013-06-11 |
| 23 | 1988-KOLNP-2007-(11-06-2013)-DESCRIPTION (COMPLETE).pdf | 2013-06-11 |
| 24 | 1988-KOLNP-2007-(11-06-2013)-CORRESPONDENCE.pdf | 2013-06-11 |
| 25 | 1988-KOLNP-2007-(11-06-2013)-CLAIMS.pdf | 2013-06-11 |
| 26 | 1988-KOLNP-2007-(11-06-2013)-ABSTRACT.pdf | 2013-06-11 |
| 27 | 1988-KOLNP-2007-(27-01-2016)-OTHERS.pdf | 2016-01-27 |
| 28 | 1988-KOLNP-2007-(27-01-2016)-CORRESPONDENCE.pdf | 2016-01-27 |
| 29 | 1988-KOLNP-2007-(27-01-2016)-ANNEXURE TO FORM 3.pdf | 2016-01-27 |
| 30 | 1988-KOLNP-2007_EXAMREPORT.pdf | 2016-06-30 |
| 31 | 1988-KOLNP-2007-HearingNoticeLetter.pdf | 2017-10-12 |
| 32 | 1988-KOLNP-2007-Correspondence to notify the Controller (Mandatory) [13-11-2017(online)].pdf | 2017-11-13 |